Linker, Ralf Andreas

[["dc.bibliographiccitation.artnumber","e010956"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","BMJ Open"],["dc.bibliographiccitation.volume","6"],["dc.contributor.author","Diem, Ricarda"],["dc.contributor.author","Molnar, Fanni"],["dc.contributor.author","Beisse, Flemming"],["dc.contributor.author","Gross, Nikolai"],["dc.contributor.author","Drueschler, Katharina"],["dc.contributor.author","Heinrich, Sven P."],["dc.contributor.author","Joachimsen, Lutz"],["dc.contributor.author","Rauer, Sebastian"],["dc.contributor.author","Pielen, Amelie"],["dc.contributor.author","Suehs, Kurt-Wolfram"],["dc.contributor.author","Linker, Ralf Andreas"],["dc.contributor.author","Huchzermeyer, Cord"],["dc.contributor.author","Albrecht, Philipp"],["dc.contributor.author","Hassenstein, Andrea"],["dc.contributor.author","Aktas, Orhan"],["dc.contributor.author","Guthoff, Tanja"],["dc.contributor.author","Tonagel, Felix"],["dc.contributor.author","Kernstock, Christoph"],["dc.contributor.author","Hartmann, Kathrin"],["dc.contributor.author","Kuempfel, Tania"],["dc.contributor.author","Hein, Katharina"],["dc.contributor.author","van Oterendorp, Christian"],["dc.contributor.author","Grotejohann, Birgit"],["dc.contributor.author","Ihorst, Gabriele"],["dc.contributor.author","Maurer, Julia"],["dc.contributor.author","Mueller, Matthias"],["dc.contributor.author","Volkmann, Martin"],["dc.contributor.author","Wildemann, Brigitte"],["dc.contributor.author","Platten, Michael"],["dc.contributor.author","Wick, Wolfgang"],["dc.contributor.author","Heesen, Christoph"],["dc.contributor.author","Schiefer, Ulrich"],["dc.contributor.author","Wolf, Sebastian"],["dc.contributor.author","Lagreze, Wolf A."],["dc.date.accessioned","2018-11-07T10:20:35Z"],["dc.date.available","2018-11-07T10:20:35Z"],["dc.date.issued","2016"],["dc.description.abstract","Introduction Optic neuritis leads to degeneration of retinal ganglion cells whose axons form the optic nerve. The standard treatment is a methylprednisolone pulse therapy. This treatment slightly shortens the time of recovery but does not prevent neurodegeneration and persistent visual impairment. In a phase II trial performed in preparation of this study, we have shown that erythropoietin protects global retinal nerve fibre layer thickness (RNFLT-G) in acute optic neuritis; however, the preparatory trial was not powered to show effects on visual function. Methods and analysis Treatment of Optic Neuritis with Erythropoietin (TONE) is a national, randomised, double-blind, placebo-controlled, multicentre trial with two parallel arms. The primary objective is to determine the efficacy of erythropoietin compared to placebo given add-on to methylprednisolone as assessed by measurements of RNFLT-G and low-contrast visual acuity in the affected eye 6months after randomisation. Inclusion criteria are a first episode of optic neuritis with decreased visual acuity to 0.5 (decimal system) and an onset of symptoms within 10days prior to inclusion. The most important exclusion criteria are history of optic neuritis or multiple sclerosis or any ocular disease (affected or non-affected eye), significant hyperopia, myopia or astigmatism, elevated blood pressure, thrombotic events or malignancy. After randomisation, patients either receive 33000 international units human recombinant erythropoietin intravenously for 3 consecutive days or placebo (0.9% saline) administered intravenously. With an estimated power of 80%, the calculated sample size is 100 patients. The trial started in September 2014 with a planned recruitment period of 30months. Ethics and dissemination TONE has been approved by the Central Ethics Commission in Freiburg (194/14) and the German Federal Institute for Drugs and Medical Devices (61-3910-4039831). It complies with the Declaration of Helsinki, local laws and ICH-GCP. Trial registration number NCT01962571."],["dc.identifier.doi","10.1136/bmjopen-2015-010956"],["dc.identifier.isi","000374052300146"],["dc.identifier.pmid","26932144"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/13259"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41917"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Bmj Publishing Group"],["dc.relation.issn","2044-6055"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0"],["dc.title","Treatment of optic neuritis with erythropoietin (TONE): a randomised, double-blind, placebo-controlled trialstudy protocol"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","14"],["dc.bibliographiccitation.journal","Journal of Neuroinflammation"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Jarius, Sven"],["dc.contributor.author","Ruprecht, Klemens"],["dc.contributor.author","Wildemann, Brigitte"],["dc.contributor.author","Kuempfel, Tania"],["dc.contributor.author","Ringelstein, Marius"],["dc.contributor.author","Geis, Christian"],["dc.contributor.author","Kleiter, Ingo"],["dc.contributor.author","Kleinschnitz, Christoph"],["dc.contributor.author","Berthele, Achim"],["dc.contributor.author","Brettschneider, Johannes"],["dc.contributor.author","Hellwig, Kerstin"],["dc.contributor.author","Hemmer, Bernhard"],["dc.contributor.author","Linker, Ralf A."],["dc.contributor.author","Lauda, Florian"],["dc.contributor.author","Mayer, Christoph A."],["dc.contributor.author","Tumani, Hayrettin"],["dc.contributor.author","Melms, Arthur"],["dc.contributor.author","Trebst, Corinna"],["dc.contributor.author","Stangel, Martin"],["dc.contributor.author","Marziniak, Martin"],["dc.contributor.author","Hoffmann, Frank"],["dc.contributor.author","Schippling, Sven"],["dc.contributor.author","Faiss, Juergen H."],["dc.contributor.author","Neuhaus, Oliver"],["dc.contributor.author","Ettrich, Barbara"],["dc.contributor.author","Zentner, Christian"],["dc.contributor.author","Guthke, Kersten"],["dc.contributor.author","Hofstadt-van Oy, Ulrich"],["dc.contributor.author","Reuss, Reinhard"],["dc.contributor.author","Pellkofer, Hannah L."],["dc.contributor.author","Ziemann, Ulf"],["dc.contributor.author","Kern, Peter"],["dc.contributor.author","Wandinger, Klaus-Peter"],["dc.contributor.author","Bergh, Florian Then"],["dc.contributor.author","Boettcher, Tobias"],["dc.contributor.author","Langel, Stefan"],["dc.contributor.author","Liebetrau, Martin"],["dc.contributor.author","Rommer, Paulus S."],["dc.contributor.author","Niehaus, Sabine"],["dc.contributor.author","Muench, Christoph"],["dc.contributor.author","Winkelmann, Alexander"],["dc.contributor.author","Zettl U, Uwe K."],["dc.contributor.author","Metz, Imke"],["dc.contributor.author","Veauthier, Christian"],["dc.contributor.author","Sieb, Joern P."],["dc.contributor.author","Wilke, Christian"],["dc.contributor.author","Hartung, Hans-Peter"],["dc.contributor.author","Aktas, Orhan"],["dc.contributor.author","Paul, Friedemann"],["dc.date.accessioned","2018-11-07T09:14:18Z"],["dc.date.available","2018-11-07T09:14:18Z"],["dc.date.issued","2012"],["dc.description.abstract","Background: The diagnostic and pathophysiological relevance of antibodies to aquaporin-4 (AQP4-Ab) in patients with neuromyelitis optica spectrum disorders (NMOSD) has been intensively studied. However, little is known so far about the clinical impact of AQP4-Ab seropositivity. Objective: To analyse systematically the clinical and paraclinical features associated with NMO spectrum disorders in Caucasians in a stratified fashion according to the patients' AQP4-Ab serostatus. Methods: Retrospective study of 175 Caucasian patients (AQP4-Ab positive in 78.3%). Results: Seropositive patients were found to be predominantly female (p < 0.0003), to more often have signs of co-existing autoimmunity (p < 0.00001), and to experience more severe clinical attacks. A visual acuity of <= 0.1 during acute optic neuritis (ON) attacks was more frequent among seropositives (p < 0.002). Similarly, motor symptoms were more common in seropositive patients, the median Medical Research Council scale (MRC) grade worse, and MRC grades <= 2 more frequent, in particular if patients met the 2006 revised criteria (p < 0.005, p < 0.006 and p < 0.01, respectively), the total spinal cord lesion load was higher (p < 0.006), and lesions >= 6 vertebral segments as well as entire spinal cord involvement more frequent (p < 0.003 and p < 0.043). By contrast, bilateral ON at onset was more common in seronegatives (p < 0.007), as was simultaneous ON and myelitis (p < 0.001); accordingly, the time to diagnosis of NMO was shorter in the seronegative group (p < 0.029). The course of disease was more often monophasic in seronegatives (p < 0.008). Seropositives and seronegatives did not differ significantly with regard to age at onset, time to relapse, annualized relapse rates, outcome from relapse (complete, partial, no recovery), annualized EDSS increase, mortality rate, supratentorial brain lesions, brainstem lesions, history of carcinoma, frequency of preceding infections, oligoclonal bands, or CSF pleocytosis. Both the time to relapse and the time to diagnosis was longer if the disease started with ON (p < 0.002 and p < 0.013). Motor symptoms or tetraparesis at first myelitis and > 1 myelitis attacks in the first year were identified as possible predictors of a worse outcome."],["dc.identifier.doi","10.1186/1742-2094-9-14"],["dc.identifier.isi","000300949700001"],["dc.identifier.pmid","22260418"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/7222"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/27377"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Biomed Central Ltd"],["dc.relation.issn","1742-2094"],["dc.rights","CC BY 2.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/2.0"],["dc.title","Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]